KPRX - Kiora Pharmaceuticals Inc

KPRX - Kiora Pharmaceuticals Inc

https://www.kiorapharma.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Kiora Pharmaceuticals ( KPRX ) Upgraded to Strong Buy: Here's What You Should Know

Zacks Commentary • 1 month, 4 weeks ago • score: 0.36

Kiora Pharmaceuticals (KPRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Is Kiora Pharmaceuticals ( KPRX ) Stock Undervalued Right Now?

Zacks Commentary • 1 year, 2 months ago • score: 0.45

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

None

52W High

$4.18

52W Low

$2.25

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

-0.68

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

2.41

EV/EBITDA (<8 favorable)

-1.03

EV/Revenue (<3 favorable)

569.41

P/S (TTM) (<3 favorable)

363.74

P/B (<3 favorable)

0.42

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

3.19%

Institutions (25–75% balanced)

25.28%

Shares Outstanding

3,433,500

Float

2,929,500

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

-371,906

EPS (TTM)

-3.36

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.43%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

-0.0196

Previous

-0.0134

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025